Survodutide Benefits

Clinical Trials GLP-1 / Weight Loss

Founder & Lead Researcher

Reviewed by Peptide Nerds Editorial · Updated April 2026

Not medical advice. This content is for educational purposes only. Consult a healthcare provider before starting any peptide protocol. Full disclaimer.

How Survodutide works

Activates both GLP-1 and glucagon receptors. The glucagon component increases energy expenditure and hepatic fat oxidation while GLP-1 reduces appetite.

Reported benefits

Based on available research data, Survodutide has been associated with the following benefits:

Up to 19% weight loss in Phase 2
Significant liver fat reduction
Potential MASH treatment

Supporting research

Survodutide for Obesity (Phase 2)

New England Journal of Medicine, 2024 · PMID: 38587239

19.2% body weight loss at highest dose over 46 weeks.

Important context

Benefits reported in clinical trials represent average outcomes across study populations. Individual results vary based on genetics, dosage, duration, and lifestyle factors.

Survodutide overview Dosage protocol

Related peptides

Semaglutide — Average 14.9% body weight loss over 68 weeks in the STEP 1 trial (n=1,961) Tirzepatide — Average 20.9% body weight loss at 15 mg dose over 72 weeks (SURMOUNT-1, n=2,539) Retatrutide — Phase 3 (TRIUMPH-4): 28.7% average body weight loss at 68 weeks (26.6% placebo-adjusted) — approximately 71.2 lbs at the 12 mg dose (Eli Lilly topline results, December 2025; peer-reviewed publication pending)

Free Peptide Weight Loss Guide

Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.